Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00EQY
|
|||
| Former ID |
DIB008094
|
|||
| Drug Name |
KTN3379
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Kolltan pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erbb3 tyrosine kinase receptor (Erbb-3) | Target Info | . | [2] |
| KEGG Pathway | ErbB signaling pathway | |||
| Calcium signaling pathway | ||||
| Endocytosis | ||||
| Proteoglycans in cancer | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Cadherin signaling pathway | |||
| EGF receptor signaling pathway | ||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | |||
| ErbB receptor signaling network | ||||
| a6b1 and a6b4 Integrin signaling | ||||
| WikiPathways | ErbB Signaling Pathway | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Signaling Pathways in Glioblastoma | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02014909) A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors. U.S. National Institutes of Health. | |||
| REF 2 | A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4): 733-750. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.